We Venture Capital launches to invest in early-stage diagnostics startups

We Venture Capital launches to invest in early-stage diagnostics startups

Published: 07-09-2023 15:25:00 | By: Pie Kamau | hits: 3332 | Tags:

We Venture Capital, the corporate venture capital operation of Werfen, announced its launch. We Venture Capital is committed to investing in diagnostics startups, as well as digital solutions and biotechnology, surrounding the diagnostics space.

Javier Gómez, Chief Financial Officer, Werfen: "We Venture Capital is further proof of Werfen's commitment to the advancement of patient care through innovation. This vehicle allows Werfen to invest in early-stage companies, understand trends in healthcare, and be at the forefront of disruptive technologies that will shape the future of diagnostics."

Through a global reach, We Venture Capital invests primarily in Series A, and may also invest in Seed or Series B. With an early-stage focus, investments target startups close to market, or early market entrants ready to scale up. We Venture Capital actively partners with its portfolio companies and supports their growth by leveraging its knowledge of specialized diagnostics worldwide. Having an evergreen structure allows We Venture Capital to partner with portfolio companies to create long-term value all the way to the optimal point of exit.

Louise Warme, Head, We Venture Capital: "Our investment team is truly passionate about partnering with start-ups that drive change and technological disruption in the diagnostics field, and we aim to become a leader in diagnostic venture capital. We want to thank everyone who has supported this launch and for bringing We Venture Capital to life."

We Venture Capital currently holds 2 portfolio companies, operating within diagnostics and digital solutions/AI.

www.weventurecapital.com